News about Regulation

TGA Issues New Guidance on Prescription Medicine Advertising Rules

TGA Issues New Guidance on Prescription Medicine Advertising Rules

Australia’s Therapeutic Goods Administration (TGA) has released updated guidance on prescription medicine advertising restrictions, providing practical examples to help businesses and individuals understand compliance requirements and meet their regulatory obligations.

Regulation | 19/06/2026 | By News Bureau

IPC Represents India at the 16th International Meeting of World Pharmacopoeias in Brazil

IPC Represents India at the 16th International Meeting of World Pharmacopoeias in Brazil

The Indian Pharmacopoeia Commission (IPC) represented India at the 16th International Meeting of World Pharmacopoeias in Brazil, highlighting advances in pharmacopoeial standards and global harmonisation. India’s leadership in setting quality standards for complex medicines and strengthening international regulatory collaboration was widely recognised.

Regulation | 18/06/2026 | By News Bureau

Allergan Aesthetics Secures US FDA Approval for Skinvive to Treat Neck Wrinkles

Allergan Aesthetics Secures US FDA Approval for Skinvive to Treat Neck Wrinkles

Allergan Aesthetics has received the US Food and Drug Administration (FDA) approval for Skinvive by Juvéderm to reduce neck wrinkles and improve overall neck appearance. The injectable treatment helps the skin retain moisture, softness and smoothness, providing a first-of-its-kind option for addressing age-related and ‘tech-neck’ lines.

Regulation | 18/06/2026 | By News Bureau

US FDA Expands OTC Access to Naloxone Nasal Spray for Opioid Overdose

US FDA Expands OTC Access to Naloxone Nasal Spray for Opioid Overdose

US FDA expands Over-the-Counter (OTC) access to naloxone nasal spray for opioid overdose, supporting efforts to prevent overdose deaths and strengthen addiction recovery initiatives under the US government’s public health strategy.

Regulation | 18/06/2026 | By News Bureau

Zai Lab Secures EMA Orphan Drug Status for Zoci in Pulmonary Neuroendocrine Carcinomas

Zai Lab Secures EMA Orphan Drug Status for Zoci in Pulmonary Neuroendocrine Carcinomas

Zai Lab has received EMA Orphan Drug Designation (ODD) for zocilurtatug pelitecan (zoci) in pulmonary neuroendocrine carcinomas. The designation recognises promising clinical data suggesting potential benefits over existing therapies for patients with relapsed or refractory extensive-stage Small Cell Lung Cancer (SCLC).

Regulation | 17/06/2026 | By News Bureau

US FDA Classifies Aurobindo Pharma's Eugia Unit-III Inspection as Official Action Indicated

US FDA Classifies Aurobindo Pharma's Eugia Unit-III Inspection as Official Action Indicated

Aurobindo Pharma said the US FDA has classified its inspection of Eugia Unit-III in Telangana as Official Action Indicated, while reaffirming its commitment to maintaining global quality manufacturing standards.

Regulation | 16/06/2026 | By News Bureau 198

Health Ministry Ends Cough Syrup Sale Exemption in Villages

Health Ministry Ends Cough Syrup Sale Exemption in Villages

The Union Ministry of Health and Family Welfare has amended the Drugs Rules, 1945, withdrawing the exemption for cough syrup sales in small villages. The move strengthens regulatory oversight and aims to improve monitoring, safety, and control of cough syrup distribution across India.

Regulation | 16/06/2026 | By News Bureau

US FDA Accepts Gilead's Once-Weekly Yeztugo for HIV Prevention

US FDA Accepts Gilead's Once-Weekly Yeztugo for HIV Prevention

Gilead’s investigational once-weekly oral HIV prevention pill Yeztugo has been accepted for US FDA review, supported by strong clinical data showing high efficacy of lenacapavir in preventing HIV across 2 clinical trials. The therapy could become the first long-acting oral option for HIV prevention.

Regulation | 16/06/2026 | By News Bureau

US FDA Approves KEYTRUDA-WELIREG Combination for Adjuvant ccRCC

US FDA Approves KEYTRUDA-WELIREG Combination for Adjuvant ccRCC

The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for the adjuvant treatment of certain patients with clear cell Renal Cell Carcinoma (ccRCC). The approval expands treatment options for kidney cancer patients at high risk of recurrence following surgery.

Regulation | 15/06/2026 | By News Bureau

US FDA Approves Bayer's AMBELVIST for Contrast-Enhanced MRI

US FDA Approves Bayer's AMBELVIST for Contrast-Enhanced MRI

Bayer’s AMBELVIST (gadoquatrane) has received US FDA approval for contrast-enhanced MRI to detect and visualise lesions with abnormal vascularity in the Central Nervous System (CNS) and other body regions. The approval expands advanced imaging options with a next-generation gadolinium-based contrast agent for improved diagnostic evaluation.

Regulation | 15/06/2026 | By News Bureau 118

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members